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Objective: To evaluate the effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase (MDP-EL) in 
comparison with standard GnRH agonist luteal long protocol (LP) in each non-obese and obese polycystic ovary syndrome (PCOS) women un-
dergoing IVF.
Methods: Two hundred eleven infertile women with PCOS were recruited and randomized to undergo either GnRH antagonist MDP-EL (an-
tagonist group) or standard GnRH agonist luteal LP (agonist group). IVF cycle outcomes were compared between the two groups.
Results: Total dose and days of recombinant human follicle stimulating hormone (rhFSH) administered were significantly fewer in the antago-
nist group than in the agonist group. Incidence of severe ovarian hyperstimulation syndrome was significantly lower in the antagonist group. 
However, IVF and pregnancy outcomes were similar in the two groups. When all subjects were divided into non-obese and obese subgroups, 
in non-obese PCOS subgroup, IVF and pregnancy outcomes were comparable in the antagonist and agonist groups but total dose and days of 
rhFSH were also significantly fewer in the antagonist group. Similar findings were also observed in obese PCOS subgroup.
Conclusion: GnRH antagonist MDP-EL is at least as effective as GnRH agonist LP and may be a more patient-friendly alternative in controlled 
ovarian stimulation for PCOS patients undergoing IVF, independent of body mass index.
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Introduction 
Polycystic ovary syndrome (PCOS) is the most common cause of 
anovulatory infertility, affecting 5% to 10% of women of reproduc-
tive age [1]. PCOS is associated with elevated androgen levels and/or 
chronic anovulation, ultimately leading to menstrual disorders includ-
ing amenorrhea, oligomenorrhea, and infertility [2]. 
Infertile patients with PCOS women are frequently faced with diffi-
cult problems in ovulation induction (OI) or controlled ovarian stimu-
lation (COS). Hypersecretion of LH and hyperandrogenemia are thou-
ght to be associated with decreased oocyte quality, lower fertiliza-
tion, lower implantation lower pregnancy, and increased miscarriage 
rates [3]. Therefore, there is a theoretical benefit in the use of GnRH 
analogues in COS cycles, especially in patients with PCOS. Actually, 
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GnRH agonists administration before and during ovarian stimulation 
causes a significant reduction in the incidence of premature LH surg-
es and the frequency of cycle cancellation, thus increasing the suc-
cess rate of IVF-ET [4,5]. Therefore, GnRH agonist long protocol (LP) 
has been commonly used for IVF cycles in PCOS patients. However, 
GnRH agonist LP has certain drawbacks, including the need to ad-
minister the agents for more than 2 weeks to induce pituitary desen-
sitization, an unnecessary elevation of gonadotropin levels during 
early administration of GnRH agonists, and high costs attributable to 
the increased total dose and a higher number of days of gonadotro-
pin administration. Moreover, this protocol cannot reduce the inci-
dence of ovarian hyperstimulation syndrome (OHSS) in COS cycles. 
This shortcoming of GnRH agonist LP may be more problematic in 
PCOS patients whose ovaries are very sensitive to stimulation and of-
ten develop excessive follicular development in response to exoge-
neous gonadotropin.
GnRH antagonists that were recently introduced for COS have sev-
eral advantages over GnRH agonists. They bind competitively to the 
GnRH receptors in pituitary, and produce an immediate and rapid 
decrease in LH and FSH levels without GnRH receptor desensitization 
as well as flare-up effect. COS protocols using GnRH antagonists have 
been shown to be effective in preventing premature LH surge [6,7]. 
Furthermore, meta-analyses in general population demonstrated 
that GnRH antagonist protocols reduce the incidence of OHSS as well 
as the amount of gonadotropins used and the duration of stimula-
tion as compared with GnRH agonist protocols [8,9]. However, these 
meta-analyses showed an inconsistent results on pregnancy out-
come. Moreover, there are very limited studies comparing GnRH an-
tagonist protocol and GnRH agonist LP in PCOS patients [10-14] and 
the optimal stimulation protocol for these patients is still under de-
bate.
Therefore, this study was performed to investigate the effective-
ness of GnRH antagonist multiple dose protocol applied during early 
and late follicular phase (MDP-EL) compared with the standard GnRH 
agonist luteal LP in PCOS patients undergoing IVF-ET.
Methods
1. Patient population
Our prospective randomized study was performed at a university-
based infertility clinic at the Asan Medical Center, Seoul, South Korea. 
The study population consisted of 211 infertile women with PCOS who 
had undergone 211 IVF cycles between January 2003 and March 2008. 
The Institutional Review Board of our center approved the study 
and all patients provided written informed consent. The subjects, 
aged 25 to 39 years, were randomized into either the GnRH antago-
nist MDP-EL (antagonist group, n=106) or the GnRH agonist LP (ag-
onist group, n=105) by the use of sealed envelopes and a computer-
generated list. The sequence of allocation to the two groups was pro-
vided to the investigating physicians and randomization was perform-
ed as planned according to the randomization list order. 
The PCOS diagnosis was based on the revised PCOS diagnostic cri-
teria of the 2003 Rotterdam consensus [15]. All patients were in good 
health with normal cardiac, hepatic and renal functions, and they 
had experienced spontaneous onset of puberty and normal sexual 
development. None of subjects had ever taken any hormonal thera-
py within the preceding three months. 
2. Ovarian stimulation protocols
All patients received oral contraceptive (OC, Diane35; Bayer Scher-
ing Pharma, Berlin, Germany) pretreatment for 21 days in the cycle 
preceding ovarian stimulation. In the antagonist group, 5 days after 
discontinuation of OC, ovarian stimulation was commenced using 50 
to 150 IU of recombinant human FSH (rhFSH, Gonal-F; Merck Serono 
SA, Geneva, Switzerland) after establishing ovarian and uterine qui-
escence using vaginal ultrasound. RhFSH was administered in a step-
up fashion and the dose of rhFSH was adjusted every 3 to 4 days ac-
cording to ovarian response. GnRH antagonist, cetrorelix (Cetrotide; 
Merck Serono SA) 0.125 mg/day was administered in the morning of 
stimulation day 1 and 2. When the mean diameter of lead follicle re-
ached 13 mm, cetrorelix at a dose of 0.25 mg/day was started again 
and continued daily up to the day of recombinant hCG (rhCG, Ovi-
drel; Merck Serono SA) injection. 
In the agonist group, GnRH agonist, triptorelin (Decapeptyl; Ferring, 
Malmo, Sweden) at a dose of 0.1 mg/day was initiated from day 18 of 
OC pretreatment cycle. All patients had withdrawal bleeding after 
discontinuation of OC. When pituitary desensitization was achieved, 
ovarian stimulation was started and the dose of triptorelin was re-
duced to 0.05 mg daily and continues up to day of rhCG administra-
tion. Ovarian stimulation was performed in the same manner with the 
antagonist group. 
In both antagonist and agonist groups, rhCG of 250 μg was admin-
istered subcutaneously to induce follicular maturation when one or 
more follicles reached a mean diameter of 17 mm. Transvaginal ultra-
sound-guided oocyte retrieval was performed 36 hours after rhCG 
injection, and one to four embryos, after IVF or ICSI, were transferred 
into the uterus on the 3rd day after oocyte retrieval. Luteal support 
was provided by administering 90 mg of vaginal progesterone gel 
(Crinone gel 8%; Merck Serono SA) once daily from the day of oocyte 
retrieval. Pregnancies were confirmed by rising serum β-hCG concen-
trations and transvaginal ultrasonographic evidence of a gestational 
sac. The serum level of β-hCG was measured 11 days after embryo 
transfer (ET). Measurement of β-hCG was performed by radioimmu-
noassay using a hCG MAIAclone kit (Serono Diagnostics, Woking, Sur-  http://dx.doi.org/10.5653/cerm.2012.39.1.22
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rey, UK). Inter- and intra-assay variances were not more than 10% and 
5%, respectively. Measurement of estradiol and progesterone was 
performed by radioimmunoassay using a Coat-A-Count Estradiol kit 
(Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA) and a 
Coat-A-Count Progesterone kit (Siemens Medical Solutions Diagnos-
tics); interassay and intraassay variances in measuring estradiol and 
progesterone were less than 10% and 5%, respectively. 
3. Outcome measures 
Primary efficacy endpoint was clinical pregnancy rate per cycle. Se-
condary efficacy variables included total amount and days of rhFSH 
administered, the numbers of retrieved, mature, fertilized oocytes 
and good quality embryos, embryo implantation rate, miscarriage 
rate, and the incidence of severe OHSS. OHSS was diagnosed and 
classified in accordance with the classification system proposed by 
Golan et al. [16]. Clinical pregnancy was defined as the presence of a 
gestational sac by ultrasonography, while miscarriage rate per clini-
cal pregnancy was defined as the proportion of patients who failed 
to continue development before 24 weeks of gestation in all clinical 
pregnancies. Preterm birth was defined as the delivery at or before 
34 weeks of gestation. Live birth was defined as the delivery of a fe-
tus with signs of life after twenty completed weeks of gestational age.
4. Statistical analysis
The mean value was expressed as the mean±SD. Statistical analy-
sis for the comparisons of mean values was performed using Student’s 
t-test. Chi-square test and Fisher’s exact test were used for the com-
parisons of fraction. Statistical significance was defined as p<0.05. 
All analyses were performed using the SPSS ver. 11.0 (SPSS Inc, Chi-
cago, IL, USA). 
Results
The antagonist group and agonist group were comparable with re-
spect to patients’ characteristics such as the age of patients, infertility 
duration, body mass index (BMI), the proportion of nullipara, antral 
follicle count, basal endocrine profile and 2-hour glucose level after a 
75 g glucose load (Table 1). 
The antagonist group consisted of 106 cycles initiated correspond-
ing to 106 patients, and the agonist group consisted of 105 cycles 
initiated corresponding to 105 patients. One cycle (0.9%) in the an-
tagonist group and 2 cycles (1.9%) in the agonist group were cancelled 
after oocyte retrieval due to a high risk of OHSS. There was no signifi-
cant difference in cycle cancellation rate between the two groups. 
Table 2 presents the comparison of COS results and IVF outcomes 
between the antagonist and agonist groups. Total days and dose of 
rhFSH required for COS were significantly fewer in the antagonist 
group than in the agonist group (p<0.001 and p=0.003, respective-
ly) (Table 2). There were no significant differences between the two 
groups with respect to serum concentrations of progesterone and 
estradiol on the day of hCG injection, and the numbers of oocytes re-
trieved, mature oocytes, fertilized oocytes, grade I or II embryos, em-
bryos transferred and embryos cryopreserved (Table 2). The two groups 
were similar in the clinical pregnancy rate per cycle initiated and per 
ET cycle, embryo implantation rate, live birth rate per ET cycle and 
multiple pregnancy rate (Table 2). However, the incidence of severe 
OHSS was significantly lower in the antagonist group of 0.9% (1/106), 
compared with 7.6% (8/105) in the agonist group (p=0.019) (Table 
2). Of all patients with severe OHSS, 1 in the antagonist group and 7 
in the agonist group became pregnant. All of the patients who suf-
fered from severe OHSS were hospitalized and discharged without 
any complications. 
All subjects were divided into non-obese subgroup (BMI<23 kg/
m
2) and obese subgroup (BMI≥23 kg/m
2). In the non-obese sub-
group, total days and dose of rhFSH required were also significantly 
fewer in the antagonist group than in the agonist group (p<0.001 
and p=0.012, respectively) (Table 3). IVF and pregnancy outcomes 
were also comparable in the two groups (Table 3). The incidence of 
severe OHSS seemed to be lower in the antagonist group, but the 
difference did not achieve a statistical significance (p=0.113) (Table 
3). Similar results were observed in the obese subgroup consisted of 
Table 1. Patients’ characteristics 
GnRH antagonist 
MDP-EL
GnRH agonist 
LP p-value
No. of patients 106 105
Age of patients (yr) 32.5±4.5 32.2±4.2 NS
a
Age of husbands (yr) 36.4±4.9 36.9±4.8 NS
a
Infertility duration (yr)  3.3±1.6  3.1±1.3 NS
a
BMI (kg/m
2) 22.9±3.1 22.7±2.9 NS
a
No. of nullipara  64 (60.4) 66 (62.9) NS
b
AFC 27.7±4.1 26.5±3.9 NS
a
Fasting glucose (mg/dL)  97.4±20.1  96.4±18.4 NS
a
Two-hour glucose after 75 g 
glucose load (mg/dL)
132.5±27.8 128.5±24.6 NS
a
Endocrine profile
Basal FSH (IU/L)  4.2±1.3  4.3±1.0 NS
a
Basal LH (IU/L)  7.5±1.7  7.2±1.6 NS
a
Basal T (ng/mL)  1.2±0.5  1.1±0.4 NS
a
Basal free T (pg/mL)  1.3±0.6  1.3±0.6 NS
a
DHEAS (ng/mL) 2,148.7±322.5  2,111.2±299.7 NSa
PRL (ng/mL) 16.5±3.4 16.1±3.3 NS
a
IGF-1 (ng/mL) 302.1±64.1 312.4±59.5 NS
a
Values are presented as mean±SD or number (%).
MDP-EL, multiple-dose protocol during early and late follicular phase; LP, long 
protocol; NS, not significant; BMI, body mass index; AFC, antral follicle count; 
IGF-1, Insulin like growth factor -1.
aStudent’s t-test; 
bChi-square test. www.eCERM.org
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PCOS women with BMI ≥23 kg/m
2 (Table 4).
Discussion
This study evaluated the effectiveness of GnRH antagonist MDP-EL 
compared with the standard GnRH agonist luteal LP in PCOS patients 
undergoing IVF-ET. We used the GnRH antagonist MDP-EL to correct 
for hormonal abnormalities seen during the early follicular phase, 
rather than employing the standard GnRH antagonist MDP during 
the late follicular phase. Our findings suggest that the GnRH antago-
nist protocol for COS can be applied to PCOS patients and GnRH an-
tagonist MDP-EL may be beneficial in reducing total days and dose 
of rhFSH required and the incidence of severe OHSS in PCOS patients 
undergoing IVF-ET. 
Particular attention should be paid during OI or COS in PCOS pati-
ents, because ovaries of PCOS patients have a surplus number of small 
antral follicles and these patients are exposed to the risks of OHSS. 
Despite special attention, complications, such as OHSS, multiple pre-
gnancy and premature luteinization, are usually more frequent in 
women with PCOS [17]. Other characteristics of women with PCOS, 
including elevated basal serum LH, hyperandrogenemia, and increased 
intrafollicular androgen levels have been shown to adversely affect 
COS or IVF results by interrupting the development of normal follicles 
and inducing degeneration of mature follicles. The miscarriage rate is 
therefore higher in PCOS than in normal women [3]. To overcome 
these problems, GnRH agonist was introduced for COS in PCOS pa-
tients and its use effectively prevented premature luteinization, in-
creased pregnancy rate, and decreased miscarriage frequency [4,5]. 
However, the use of GnRH agonist cannot reduce the incidence of 
OHSS in PCOS patients undergoing COS. This is an important reason 
to seek new treatment option than GnRH agonist LP in PCOS patients 
at high risk of OHSS.
Recently, GnRH antagonist protocols have been reported to reduce 
the incidence of OHSS as well as days and dose of gonadotropins re-
quired when compared with GnRH agonist protocols [8,9] and there-
fore the use of GnRH antagonists has been proposed as a new safer 
Table 2. Comparison of COS results and IVF/ICSI outcome in all sub-
jects
GnRH antago-
nist MDP-EL
GnRH agonist 
LP p-value
No. of cycles initiated 106 105
No. of ET cycles 105 103
No. of cycles cancelled 1 (0.9) 2 (1.9)  NS
a
No. of cycles with ICSI 42 (39.6) 38 (36.2)  NS
a
Days of rhFSH  10.8±1.9 12.2±2.0  <0.001
a
Total dose of rhFSH (IU) 1,423.4±563.6 1,670.8±610.6      0.003
a
On the day of hCG injection
Progesterone (ng/mL) 0.3±0.2 0.3±0.2  NS
a
Estradiol (pg/mL)  2,175.1±618.1 2,255.4±627.1  NS
a
Endometrial thickness (mm) 10.3±1.3 10.3±1.3  NS
a
No. of oocytes retrieved 14.7±5.8 14.2±5.8  NS
a
No. of mature oocytes 12.5±4.8 12.3±5.0  NS
a
No. of fertilized oocytes 12.3±4.7 12.1±4.9   NS
a
No. of grade I, II embryos  4.0±2.2  4.1±2.1  NS
a
No. of embryos transferred  3.0±0.5  2.9±0.6  NS
a
No. of embryos cryopreserved  4.1±4.3  4.3±4.5  NS
a
Clinical PR per cycle initiated (%) 38.7 (41/106) 38.1 (40/105)  NS
b
Clinical PR per ET (%) 39.0 (41/105) 38.8 (40/103)  NS
b
Multiple PR (%) 19.5 (8/41) 20.0 (8/40)  NS
b
Miscarriage rate (%) 12.2 (5/41) 10.0 (4/40)  NS
b
Embryo implantation rate (%) 16.7 (52/311) 16.7 (50/299)  NS
b
Live birth rate per ET (%) 34.3 (36/105) 35.0 (36/103)  NS
b
Severe OHSS (%)  0.9 (1/106)   7.6 (8/105)  0.019
b
Values are presented as number (%), mean±SD, or % (number/total number).
COS, controlled ovarian stimulation; MDP-EL, multiple-dose protocol during 
early and late follicular phase; LP, long protocol; ET, embryo transfer; NS, not 
significant; rhFSH, recombinant human follicle stimulating hormone; PR, pre-
gnancy rate; OHSS, ovarian hyperstimulation syndrome.
aStudent’s t-test; 
bChi-square test or Fisher’s exact test. 
Table 3. Comparison of COS results and IVF/ICSI outcome in patients 
with BMI<23 kg/m
2
GnRH antago-
nist MDP-EL
GnRH agonist 
LP p-value
No. of cycles initiated 55 54
No. of ET cycles 54 52
No. of cycles cancelled 1 (1.8) 2 (3.7) NS
a
No. of cycles with ICSI 21 (38.2) 18 (33.3) NS
a
Days of rhFSH  9.7±1.3 11.2±1.5 <0.001
a
Total dose of rhFSH (IU) 1,077.9±326.9 1,241.3±340.4      0.012
a
On the day of hCG injection
Progesterone (ng/mL) 0.4±0.2 0.3±0.2 NS
a
Estradiol (pg/mL)  2,217.3±547.9 2,295.0±555.0 NS
a
Endometrial thickness (mm) 10.3±1.1 10.4±1.2 NS
a
No. of oocytes retrieved 15.0±4.9 14.7±5.2 NS
a
No. of mature oocytes 13.3±4.5 12.8±4.7 NS
a
No. of fertilized oocytes 12.9±4.3 12.4±4.8 NS
a
No. of grade I, II embryos 4.1±2.2 3.8±2.2 NS
a
No. of embryos transferred 3.0±0.5 2.9±0.6 NS
a
No. of embryos cryopreserved 4.5±4.1 4.2±4.7 NS
a
Clinical PR per cycle initiated (%) 41.8 (23/55) 40.7 (22/54) NS
b
Clinical PR per ET (%) 42.6 (23/54) 42.3 (22/52) NS
b
Multiple PR (%) 26.1 (6/23) 22.7 (5/22) NS
b
Miscarriage rate (%) 4.3 (1/23) 4.5 (1/22) NS
b
Embryo implantation rate (%) 19.1 (31/162) 18.5 (28/151) NS
b
Live birth rate per ET (%) 40.7 (22/54) 40.4 (21/52) NS
b
Severe OHSS (%) 1.8 (1/55) 9.3 (5/54) NS
b
Values are presented as number (%), mean±SD, or % (number/total number).
COS, controlled ovarian stimulation; MDP-EL, multiple-dose protocol during 
early and late follicular phase; LP, long protocol; ET, embryo transfer; NS, not 
significant; rhFSH, recombinant human follicle stimulating hormone; PR, pre-
gnancy rate; OHSS, ovarian hyperstimulation syndrome.
aStudent’s t-test; 
bChi-square test or Fisher’s exact test.   http://dx.doi.org/10.5653/cerm.2012.39.1.22
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stimulation option for PCOS patients. However, there is limited num-
ber of published studies on the use of GnRH antagonists in COS for 
PCOS patients, and an optimal GnRH antagonist protocol for these 
patients is still controversial. 
During COS using GnRH antagonists in PCOS women, elevated LH 
and estradiol levels in the early follicular phase may adversely affect 
oocyte or embryo quality and may decrease endometrial acceptabil-
ity and pregnancy rates [15]. For this reason, it has been recommend-
ed to use GnRH antagonists in the early follicular phase of GnRH an-
tagonist cycles in these patients [11-13]. Elkind-Hirsch et al. [11] de-
monstrated the effectiveness and safety of concurrent ganirelix and 
follitropin-beta therapy for COS in women with PCOS. In addition, 
pregnancy outcomes in PCOS patients pretreated with OC followed 
by concomitant administration of cetrorelix from the first day of stim-
ulation, were similar to those of PCOS patients treated with GnRH ag-
onist LP [12]. In our preliminary study [13], two additional use of GnRH 
antagonist in the early follicular phase of standard GnRH antagonist 
MDP cycle also yielded comparable IVF results and pregnancy out-
come with fewer dose and days of rhFSH used when compared with 
those of GnRH agonist LP. The present study corroborates the find-
ings of our preliminary study. Meta-analysis by Griesinger et al. [18] 
showed similar pregnancy outcomes when GnRH antagonist proto-
cols and GnRH agonist LP were compared in PCOS patients undergo-
ing IVF-ET. In a randomized controlled trial (RCT) by Lainas et al. [14], 
even standard GnRH antagonist MDP also resulted in a similar preg-
nancy rate and lower incidence of severe OHSS, compared with GnRH 
agonist LP. So far, there are limited data on COS using GnRH antago-
nist in PCOS patients and furthermore, there are very few published 
studies supporting benefits of GnRH antagonist protocols in PCOS 
patients.
This study showed that GnRH antagonist protocol reduces the inci-
dence of severe OHSS in PCOS patients as compared with GnRH ago-
nist LP. In RCT by Lainas et al. [14], severe OHSS also occurred less fre-
quently in the antagonist group than in the agonist group, although 
same dose of hCG was administered in both groups. The explanation 
for this finding is that GnRH antagonist itself may have a slowing ef-
fect of excessive follicular development, especially in the secondary 
follicles. 
Compared with non-obese women with PCOS, obese women with 
PCOS have various endocrine changes. High BMI is associated with 
gonadotropin resistance and poor IVF outcome [19,20]. In addition, 
high BMI has an inhibitory effect on LH [21]. Therefore, GnRH antago-
nist protocol in obese PCOS women is likely to work differently than 
in non-obese PCOS women. For this reason, we divided all subjects 
into non-obese and obese subgroups, and then evaluated the effec-
tiveness of GnRH antagonist MDP-EL in each subgroups. In non-obese 
subgroup, IVF results and pregnancy outcome were comparable but 
total dose and days of rhFSH were significantly fewer in the antago-
nist group than in the agonist group. Similar results were also observ-
ed in obese subgroup. Our results implies that GnRH antagonist MDP-
EL is effective not only in non-obese PCOS patients with theoretically 
higher LH levels but also in obese PCOS patients. 
In conclusion, GnRH antagonist MDP-EL can provide similar IVF out-
come with fewer dose and days of rhFSH administered in both non-
obese and obese PCOS patients, compared with GnRH agonist LP. 
Moreover, GnRH antagonist MDP-EL can reduce the incidence of se-
vere OHSS. These findings suggest that the GnRH antagonist MDP-EL 
can be more cost-effective, more patient-friendly and safer than GnRH 
agonist LP in PCOS patients. Therefore, GnRH antagonist protocol may 
be the protocol of choice for COS in PCOS patients undergoing IVF-
ET, independent of BMI.
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Table 4. Comparison of COS results and IVF/ICSI outcomes in patients 
with BMI≥23 kg/m
2
GnRH antago-
nist MDP-EL
GnRH agonist 
LP p-value
No. of cycles initiated 51 51
No. of ET cycles 51 51
No. of cycles cancelled   0   0 NS
a
No. of cycles with ICSI 21 (41.2) 20 (39.2) NS
a
Days of rhFSH 12.0±1.8 13.2±2.0 0.004
a
Total dose of rhFSH (IU) 1,796.1±527.8 2,125.6±492.5 0.002
a
On the day of hCG injection
Progesterone (ng/mL) 0.3±0.2 0.3±0.2 NS
a
Estradiol (pg/mL) 2,129.5±688.5 2,213.5±698.6 NS
a
Endometrial thickness (mm) 10.3±1.4 10.2±1.4 NS
a
No. of oocytes retrieved 14.4±6.6 13.7±6.3 NS
a
No. of mature oocytes 12.3±5.7 11.6±5.2 NS
a
No. of fertilized oocytes 11.8±5.6 11.2±5.0 NS
a
No. of grade I, II embryos 3.9±2.3 3.7±2.0 NS
a
No. of embryos transferred 3.0±0.6 2.9±0.5 NS
a
No. of embryos cryopreserved 3.6±4.5 3.1±4.2 NS
a
Clinical PR per cycle initiated (%) 35.3 (18/51) 35.3 (18/51) NS
b
Clinical PR per ET (%) 35.3 (18/51) 35.3 (18/51) NS
b
Multiple PR (%) 11.1 (2/18) 16.7 (3/18) NS
b
Miscarriage rate (%) 22.2 (4/18) 16.7 (3/18) NS
b
Embryo implantation rate (%) 13.7 (21/153) 14.9 (22/148) NS
b
Live birth rate per ET (%) 27.5 (14/51) 29.4 (15/51) NS
b
Severe OHSS (%)   0 5.9 (3/51) NS
b
Values are presented as number (%), mean±SD, or % (number/total number).
COS, controlled ovarian stimulation; MDP-EL, multiple-dose protocol during 
early and late follicular phase; LP, long protocol; ET, embryo transfer; NS, not 
significant; rhFSH, recombinant human follicle stimulating hormone; PR, pre-
gnancy rate; OHSS, ovarian hyperstimulation syndrome. 
aStudent’s t-test; 
bChi-square test or Fisher’s exact test.www.eCERM.org
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